| Eylea (aflibercept intravitreal) / Bayer, Regeneron |
NCT01640171: Anesthesia Preference for Intravitreal Injection: Topical or Subconjunctival |
|
|
| Completed | N/A | 57 | US | Xylocaine 2% Injectable Anesthetic, Lidocaine, Subconjunctival, Anesthesia, Anesthetic, Proparacaine Hydrochloride 0.5% Drop, Topical, Tetravisc 0.5% Gel, topical, Acuvail, anti-inflammatory, ketorolac, Intra-vitreal Anti-VEGF Drug, Lucentis, Avastin, Eylea | Retina Vitreous Associates of Florida | Age-related Macular Degeneration, Central Retinal Vein Occlusion, Diabetic Macular Edema | 09/13 | 10/13 | | |
NCT02126904: Comparison of the Time to Recurrence Between Ranibizumab and Aflibercept |
|
|
| Unknown status | N/A | 200 | Japan | IVA group | Yokohama City University Medical Center, Novartis Pharmaceuticals | The Injection Burden | 10/13 | | | |
NCT01526070: Study of Bimonthly VEGF Trap-Eye Compared to As-needed Administration or Other Therapy for Exudative Age-Related Macular Degeneration |
|
|
| Completed | N/A | 142 | US | Intravitreal injection of Aflibercept | Stanford University | Exudative Age-related Macular Degeneration | 07/14 | 07/14 | | |
NCT02000102: Outcomes of Diabetic Macula Edema Patients Switched to Aflibercept From Bevacizumab and/or Ranibizumab |
|
|
| Completed | N/A | 14 | US | Intravitreal Injection of Aflibercept | Stanford University | Diabetic Macular Edema | 09/14 | 09/14 | | |
NCT01918371: A Retrospective Study of Anti-Vascular Endothelial Growth Factor (VEGF) Injections for Retinal Vein Occlusion or Diabetic Macular Edema |
|
|
| Completed | N/A | 323 | US | Anti-VEGF, Avastin®, Lucentis®, Eylea® | Allergan | Retinal Vein Occlusion, Macular Edema | 09/14 | 09/14 | | |
AVA, NCT01965041: Intravitreal Aflibercept Injections In The Treatment Of Pattern Dystrophy |
|
|
| Withdrawn | N/A | 0 | US | aflibercept, eylea | Manhattan Eye, Ear & Throat Hospital, Northwell Health | Pattern Dystrophy of Macula | 11/14 | 11/14 | | |
NCT02291887: Genetic Analysis of Patients Responsive to Ranibizumab But Resistant to Aflibercept |
|
|
| Completed | N/A | 13 | US | Ranibizumab, Lucentis, Aflibercept, Eylea | Associated Retinal Consultants, Michigan, Genentech, Inc. | Age-Related Macular Degeneration | 07/15 | 07/15 | | |
NCT01746875: A Study Testing if Medicine Can Make Pigment Epithelium Detachments Regress and Stabilize the Vision in Eyes |
|
|
| Terminated | N/A | 9 | Europe | Aflibercept, Verteporfin | Norwegian University of Science and Technology | Macular Degeneration, Retinal Detachment | 09/15 | 09/15 | | |
NCT01711879: Use of Intravitreal Aflibercept Injection for Neovascular Glaucoma |
|
|
| Completed | N/A | 7 | US | Aflibercept, Eylea | University of Colorado, Denver | Neovascular Glaucoma | 10/15 | 10/15 | | |
NCT02005133: A Prospective, Observational, Multicentre, 2 Year Study Evaluating the Use of Eylea (Aflibercept) for the Treatment of Neovascular (Wet) Age-related Macular Degeneration in UK NHS Opthalmology Clinics |
|
|
| Terminated | N/A | 188 | Europe | | Novartis Pharmaceuticals | Wet Age-related Macular Degeneration | 10/15 | 10/15 | | |
NCT02597855: Short-term Efficacy of Intravitreal Afilibercept Depending on Subtypes of Polypoidal Choroidal Vasculopathy: Polypoidal Choroidal Neovascularization or Idiopathic Choroidal Vasculopathy |
|
|
| Unknown status | N/A | 29 | RoW | Aflibercept, Eylea, Indocyanine green angiography (intraveonus indocyanine green dye) | Yeungnam University College of Medicine | Polypoidal Choroidal Vasculopathy | 12/15 | 08/16 | | |
| Completed | N/A | 40 | US | Intravitreal Aflibercept Injection | MidAtlantic Retina, Regeneron Pharmaceuticals | Age-Related Macular Degeneration, Macular Degeneration | 03/16 | 03/16 | | |
|
NCT02541084: Caregiver Burden of Wet Age-related Macular Degeneration (wAMD) in Japan |
|
|
| Completed | N/A | 72 | Japan | Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321) | Bayer, Regeneron Pharmaceuticals | Wet Macular Degeneration | 03/16 | 07/16 | | |
NCT02585401: Evaluation of Physician Knowledge of Safety and Safe Use Information for Aflibercept in Canada |
|
|
| Completed | N/A | 99 | Canada | Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321) | Bayer, Regeneron Pharmaceuticals | Age-related Macular Degeneration (AMD), Central Retinal Vein Occlusion (CRVO), Diabetic Macular Edema (DME) | 03/16 | 05/16 | | |
NCT01942213: Observational Study to Evaluate and Compare the Rate and Extent of Inflammation After a Single Intravitreal Injection of Ranibizumab vs. a Single Intravitreal Injection of Aflibercept in Treatment Naive and Treatment Experienced Patients. |
|
|
| Completed | N/A | 136 | US | | Prism Vision Group | Neovascular Age Related Macular Degeneration | 04/16 | 04/16 | | |
SWITCH, NCT04018833: Intravitreal Ranibizumab or Aflibercept After Bevacizumab in Diabetic Macular Edema |
|
|
| Completed | N/A | 40 | NA | Ranibizumab 0.5 MG/0.05 ML Intraocular Solution [LUCENTIS], Aflibercept 40 MG/ML Intraocular Solution [EYLEA] | Bernardete Pessoa MD | Diabetic Macular Edema, Diabetic Retinopathy | 06/16 | 06/16 | | |
NCT01991730: Observational Study to Evaluate and Compare the Rate and Extent of Inflammation After a Single Injection of Ranibizumab vs. a Single Intravitreal Injection of Aflibercept in Treatment Naive and Treatment Experienced Patients |
|
|
| Recruiting | N/A | 300 | US | | NJ Retina | Age Related Macular Degeneration | 06/16 | | | |
NCT01756261: EYLEA [AMD-QOL(Age-Related Macular Degeneration-Quality of Life)] Post-marketing Surveillance in Japan |
|
|
| Completed | N/A | 757 | Japan | Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321) | Bayer, Regeneron Pharmaceuticals | Macular Degeneration | 07/16 | 02/17 | | |
NCT02218177: Intraocular Cytokines in Non-responders to Ranibizumab Treatment for Neovascular AMD |
|
|
| Completed | N/A | 30 | Canada | Aflibercept, Eylea (R), Ranibizumab, Lucentis, Combination Photodynamic Therapy | University Health Network, Toronto | Age Related Macular Degeneration | 08/16 | 12/16 | | |
NCT02615496: Evaluation of Physician and Patient Knowledge of Safety and Safe Use Information for Aflibercept |
|
|
| Completed | N/A | 716 | Europe | Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321) | Bayer, RTI Health Solutions | Macular Degeneration | 09/16 | 01/17 | | |
| Completed | N/A | 60 | NA | Aflibercept, Pranoprofen, Carotenoids | Università degli Studi di Brescia | Retinal Disease | 12/16 | 03/17 | | |
TITAN, NCT02321241: Real Life of Aflibercept in France in Patients Refractory to Ranibizumab: Observational Study in Wet AMD |
|
|
| Completed | N/A | 236 | Europe | Aflibercept (EYLEA, BAY-86-5321) | Bayer, Regeneron Pharmaceuticals | Wet Macular Degeneration | 01/17 | 08/17 | | |
PERSEUS, NCT01914380: Investigating the Effectiveness of Eylea in Patients With Wet Age-related Macular Degeneration |
|
|
| Completed | N/A | 988 | Europe | Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321) | Bayer, Regeneron Pharmaceuticals | Wet Age-related Macular Degeneration | 03/17 | 03/17 | | |
NCT03974425: One Year Results of Switching to Aflibercept for Persistent Diabetic Macular Edema Resistant to Bevacizumab |
|
|
| Completed | N/A | 37 | NA | Aflibercept Injection [Eylea] | University of Alexandria | Diabetic Macular Edema | 04/17 | 04/18 | | |
NCT02956330: Retrospective Study of the Safety and Efficacy of Patients With RVO in Subjects Who Completed Parent Study CLS1003-201 |
|
|
| Completed | N/A | 20 | US | | Clearside Biomedical, Inc. | Macular Edema, Retinal Vein Occlusion | 04/17 | 04/17 | | |
| Completed | N/A | 50 | US | Varying needle size with intravitreal ranibizumab or aflibercept, Lucentis, Eylea | Wills Eye, Mid Atlantic Retina | Age Related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion | 04/17 | 04/17 | | |
NCT03313401: Effect of Aflibercept on Human Corneal Endothelial Cells in Neovascular Age-Related Macular Degeneration |
|
|
| Completed | N/A | 34 | NA | Aflibercept, eylae, Specular microscopy, Tomey-EM-3000 | Ulucanlar Eye Training and Research Hospital | Age Related Macular Degeneration | 05/17 | 06/17 | | |
NCT01714115: Use of Eylea for the Treatment of an Optic Nerve Hemangioma |
|
|
| No Longer Available | N/A | | US | Aflibercept, Eylea, VEGF Trap-Eye | Vitreous -Retina- Macula Consultants of New York, Regeneron Pharmaceuticals | Retinal Hemangioma | | | | |
NCT02381730: Assessment of Visual Acuity in Patients With Polypoidal Choroidal Vasculopathy and Aflibercept Treatment |
|
|
| Completed | N/A | 37 | Europe | Intravitreal aflibercept | Fondation Ophtalmologique Adolphe de Rothschild | Polypoidal Choroidal Vasculopathy | 08/17 | 08/17 | | |
PEGASUS, NCT02540369: To Describe the Use of Intravitreal Aflibercept and to Describe Follow-up as Well as Treatment Patterns in Patients With Wet Age-related Macular Degeneration (wAMD) or Diabetic Macular Edema (DME) in Routine Clinical Practice in Canada. |
|
|
| Completed | N/A | 2150 | Canada | Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321) | Bayer, Regeneron Pharmaceuticals | Wet Macular Degeneration | 09/17 | 01/18 | | |
OIVAEGFFAMDIT, NCT03324542: Real World Outcomes of Intravitreal Anti-vascular Endothelial Growth Factors for Neovascular Age Related Macular Degeneration in Taiwan |
|
|
| Completed | N/A | 63 | RoW | Aflibercept [Eylea], Ranibizumab [Lucentis], Bevacizumab [Avastin] | Changhua Christian Hospital | AMD | 10/17 | 10/17 | | |
| Completed | N/A | 425 | Europe | Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321) | Bayer, Regeneron Pharmaceuticals | Eye Diseases | 11/17 | 11/17 | | |
| Completed | N/A | 48 | Europe | Navigated laser, Conventional laser | Odense University Hospital, Moorfields Eye Hospital NHS Foundation Trust | Diabetic Macular Oedema | 12/17 | 11/18 | | |
RETRO CRVO, NCT02645747: Retrospective Data Analysis of Patients Treated for Macular Edema Due to Central Retinal Vein Occlusion |
|
|
| Completed | N/A | 126 | Europe | Aflibercept (Eylea, BAY86-5321) | Bayer, Regeneron Pharmaceuticals | Retinal Vein Occlusion | 12/17 | 12/17 | | |
INSIGHT, NCT03278262: The Impact of Baseline Visual Acuity on the Treatment Outcomes in Patients Treated With AflIbercept in Real-life Clinical Setting |
|
|
| Completed | N/A | 2312 | Europe | Aflibercept (Eylea, BAY86-5321) | Bayer, Regeneron Pharmaceuticals | Wet Macular Degeneration | 12/17 | 12/17 | | |
NCT02457026: Adjunctive Photodynamic Therapy + Aflibercept vs. Afilbercept Alone for PDA in NV AMD |
|
|
| Withdrawn | N/A | 0 | US | Aflibercept, Eylea, Triamcinolone Acetonide, Triesence, Verteporfin, Visudyne | Duke University, Bausch & Lomb Incorporated | Neovascular Age-related Macular Degeneration | 01/18 | 01/18 | | |
NCT03509623: Blood Coagulation Parameters in Patients Receiving Intravitreal Aflibercept for Age-related Macular Degeneration |
|
|
| Completed | N/A | 47 | Europe | Blood sampling through direct peripheral venous puncture | University Hospital of Patras | Neovascular Age-related Macular Degeneration | 03/18 | 04/18 | | |
NCT02260687: Special Drug Use Investigation of EYLEA for Myopic Choroidal Neovascularization |
|
|
| Completed | N/A | 353 | Japan | Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321) | Bayer, Regeneron Pharmaceuticals | Choroidal Neovascularization | 04/18 | 08/18 | | |
NCT03370380: Aflibercept in Patients With Pigment Epithelial Detachments (PED) |
|
|
| Completed | N/A | 18 | Europe | Aflibercept | University Hospital Muenster | Pigment Epithelial Detachment | 04/18 | 04/18 | | |
JPMS-CRVO, NCT02040220: Prospective, Non-interventional, Multi-center Post-authorization Safety Study of Eylea for Central Retinal Vein Occlusion (CRVO) |
|
|
| Completed | N/A | 385 | Japan | Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321) | Bayer, Regeneron Pharmaceuticals | Retinal Vein Occlusion | 06/18 | 11/18 | | |
NCT04075188: Treatment of Polypoidal Choroidal Vasculopathy in Pachychoroid |
|
|
| Completed | N/A | 17 | Europe | Aflibercept Injection, verteporfin for injection | Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone Palermo | Choroidal Neovascularization, Choroid Disease | 06/18 | 07/19 | | |
| Withdrawn | N/A | 0 | NA | National Eye Institute Visual Functioning Questionnaire, NEIVFQ-25 | Timothy Jones, University Hospitals Bristol and Weston NHS Foundation Trust, Gloucestershire Hospitals NHS Foundation Trust | Diabetic Retinopathy | 08/18 | 08/18 | | |
NCT04014556: Aflibercept Plus Micropulse Laser Versus Aflibercept Monotherapy for Diabetic Macular Edema |
|
|
| Completed | N/A | 40 | NA | micropulse laser, Aflibercept | University of Alexandria | Diabetic Macular Edema | 10/18 | 12/18 | | |
ASTERIA, NCT03382587: Observational Study to Assess Intravitreal Aflibercept Injections Used in a "Treat and Extend" Regimen in Treatment-naïve Wet Age-related Macular Degeneration Patients |
|
|
| Completed | N/A | 163 | Europe | Aflibercept (Eylea, BAY86-5321) | Bayer, Regeneron Pharmaceuticals | Wet Age-related Macular Degeneration | 11/18 | 11/18 | | |
GALAXY, NCT03521895: An Integrated Analysis of the Effectiveness of Intravitreal (IVT) Aflibercept (Eylea) in Routine Clinical Practice Based on Two Large Observational Studies |
|
|
| Completed | N/A | 1000 | Europe | Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321) | Bayer | Macular Degeneration | 11/18 | 11/18 | | |
NCT01756248: EYLEA Age-Related Macular Degeneration (AMD) Post-marketing Surveillance in Japan |
|
|
| Completed | N/A | 3872 | Japan | Aflibercept(Eylea, VEGF Trap-Eye, BAY86-5321) | Bayer, Regeneron Pharmaceuticals | Macular Degeneration | 12/18 | 05/19 | | |
| Completed | N/A | 3206 | RoW | Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321) | Bayer, Regeneron Pharmaceuticals | Macular Degeneration | 12/18 | 12/18 | | |
REALE, NCT03411941: Evaluate the Effectiveness of Intravitreal (IVT) Aflibercept Injection in Clinical Practice in naïve Patients With Neovascular Age-related Macular Degeneration (nAMD) |
|
|
| Completed | N/A | 116 | Europe | Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321) | Bayer, Regeneron Pharmaceuticals | Macular Degeneration | 03/19 | 03/19 | | |
PERSEUS-IT, NCT02289924: Aflibercept (Eylea) in roUtine Clinical Practice in patientS With Wet Age-related Macular Degeneration in Italy |
|
|
| Completed | N/A | 912 | Europe | Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321) | Bayer, Regeneron Pharmaceuticals | Wet Macular Degeneration | 03/19 | 07/19 | | |
| Completed | N/A | 593 | Europe | Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321) | Bayer, Regeneron Pharmaceuticals | Wet Macular Degeneration | 04/19 | 04/19 | | |
NCT02425501: Special Drug Use Investigation of EYLEA for Diabetic Macular Edema |
|
|
| Completed | N/A | 646 | Japan | Aflibercept (Eylea, BAY86-5321) | Bayer | Macular Edema | 04/19 | 08/19 | | |
DRAKO, NCT02850263: A Study to Assess the Effectiveness of Aflibercept in Routine Clinical Practice in Patients With Diabetic Macular Oedema |
|
|
| Completed | N/A | 750 | Europe | Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321), Anti-VEGF therapies including: Eylea Aflibercept, VEGF Trap-Eye, BAY86-5321) and Ophthalmologicals / Antineovascularisation agents (S01LA05) | Bayer | Macular Edema | 05/19 | 11/20 | | |
PERSEUS-GR, NCT02821247: Prospective Observational Study to Assess Effectiveness of Intravitreal Aflibercept in Patients With Wet Macular Degeneration in Greece |
|
|
| Completed | N/A | 119 | Europe | Aflibercept (Eylea, BAY86-5321), VEGF Trap-Eye | Bayer | Choroidal Neovascularization, Macular Degeneration | 07/19 | 12/19 | | |
APOLLON, NCT02924311: Routine Clinical Practice for Use of Intravitreal Aflibercept Treatment in Patients With Diabetic Macular Edema |
|
|
| Completed | N/A | 402 | Europe | Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321) | Bayer, Regeneron Pharmaceuticals | Diabetic Retinopathy | 08/19 | 12/19 | | |
DOCTA, NCT03783832: Follow up of Diabetic Macular Edema Treated by Aflibercept (Eylea®) With OCT-Angiography |
|
|
| Unknown status | N/A | 48 | Europe | OCT ANGIOGRAPHY DATA | Aquitania Opthalmologica | Diabetic Macular Edema | 12/19 | 12/19 | | |
| Active, not recruiting | N/A | 150 | Canada | Aflibercept 40 MG/ML [Eylea], OSA diagnostic test - overnight sleep study, CPAP therapy for OSA positive patients | Uptown Eye Specialists | Diabetic Macular Edema, Sleep Apnea, Non Proliferative Diabetic Retinopathy | 03/20 | 12/20 | | |
NCT04067583: A Follow-up Physician Survey to Evaluate Physician Knowledge of Safety and Safe Use Information for Aflibercept Administered by Intravitreal Injection in Europe |
|
|
| Completed | N/A | 454 | Europe | Physician questionnaire | Bayer | Ophthalmology, Macular Degeneration | 04/20 | 04/20 | | |
MODEVA, NCT02874859: Intravitreal Aflibercept InjectiOn in Vitrectomized Eyes for Treatment of Diabetic Macular Edema |
|
|
| Completed | N/A | 49 | Europe | | Lille Catholic University, Bayer | Diabetic Macular Edema | 08/20 | 08/20 | | |
AQUILA, NCT03470103: A Study in Patients With Wet Age-related Macular Degeneration or Diabetic Macular Edema to Assess the freQuency of Use of Intravitreal Aflibercept in Routine Clinical Practices in Latin America |
|
|
| Completed | N/A | 643 | RoW | Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321) | Bayer | Macular Degeneration | 09/20 | 01/21 | | |
| Completed | N/A | 59 | Europe | Ranibizumab, Lucentis, Aflibercept, Eylea | King's College Hospital NHS Trust, King's College London | Age Related Macular Degeneration | 11/20 | 12/20 | | |
NCT05110209: Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Agerelated Macular Degeneration (AMD) Who Received Anti-VEGF Agents (IRIS Registry) |
|
|
| Completed | N/A | 331541 | US | Aflibercept, EYLEA®, Ranibizumab, LUCENTIS®, Bevacizumab, AVASTIN®; off-label use | Novartis Pharmaceuticals | Age-related Macular Degeneration (AMD) | 11/20 | 11/20 | | |
NCT06146309: Assessment Of Peri-papillary Retinal Nerve Fiber Layer Thickness In Patients With Unilateral Branch Retinal Vein Occlusion |
|
|
| Completed | N/A | 60 | RoW | aflibercept (2mg/0.05ml) | Al-Azhar University | Branch Retinal Vein Occlusion | 07/22 | 08/22 | | |
NCT05146687: Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Age-related Macular Degeneration (AMD) Who Received Anti-vascular Endothelial Growth Factor (VEGF) Agents (Komodo Health) |
|
|
| Completed | N/A | 369600 | US | Aflibercept, EYLEA®, Ranibizumab, LUCENTIS®, Bevacizumab, AVASTIN®; off-label use | Novartis Pharmaceuticals | Age-related Macular Degeneration (AMD) | 12/20 | 12/20 | | |
NCT05478967: The Effect of IVA for Preventing Postvitrectomy Hemorrhage in PDR |
|
|
| Completed | N/A | 154 | RoW | IVA injection before vitrectomy | Peking University People's Hospital, The First Affiliated Hospital with Nanjing Medical University, Shanghai 10th People's Hospital, The Affiliated Hospital of Xuzhou Medical University, The First Affiliated Hospital of Nanchang University, Nanjing Medical University, Xiamen University | Proliferative Diabetic Retinopathy | 01/21 | 02/21 | | |
AVOCT, NCT03394573: Comparison of VA Guided Versus OCT Guided TER Using Aflibercept for Diabetic Macular Edema ( Study) |
|
|
| Terminated | N/A | 110 | Europe | OCT guided treatment arm, aflibercept, VA guided treatment arm | University Hospital Inselspital, Berne | Diabetic Macular Edema | 02/21 | 02/21 | | |
ChiCTR2100048700: Efficacy in pachychoroid spectrum disorders patients treated with intravitreal aflibercept |
|
|
| Completed | N/A | 60 | | Intravitreal Aflibercept ;Intravitreal Conbercept | The First Affiliated Hospital of Soochow University; The First Affiliated Hospital of Soochow University, Su Zhou science and technology programs | pachychoroid spectrum disorders | | | | |
NCT03908723: Treatment of Macular Edema Caused by Leber's Miliary Aneurysms Using Intravitreal Aflibercept and Peripheral Laser Photocoagulation |
|
|
| Unknown status | N/A | 6 | RoW | Panretinal photocoagulation | Alexandria University | Macular Edema Caused by Leber's Miliary Aneurysms | 03/21 | 05/21 | | |
NCT04970251: Aflibercept as Adjunctive Treatment for Filtration Surgery in Neovascular Glaucoma |
|
|
| Completed | N/A | 5 | RoW | Aflibercept Ophthalmic, trabeculectomy, Panretinal photocoagulation | Siriraj Hospital | Intraocular Pressure, Neovascular Glaucoma, Vascular Endothelial Growth Factor Overexpression, Glaucoma Secondary to Eye Inflammation | 03/21 | 03/21 | | |
BELUGA, NCT04641234: A Study Reviewing Medical Records to Learn More About Treat-and-extend With Eylea in Patients With Neovascular Age-related Macular Degeneration (nAMD). |
|
|
| Completed | N/A | 330 | Europe | Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321) | Bayer | Neovascular Age-related Macular Degeneration | 06/21 | 06/21 | | |
NCT04856397: Ozurdex in Suboptimal Diabetic Macular Edema Patients |
|
|
| Not yet recruiting | N/A | 200 | NA | Intravitreal Implant in Applicator, Ozurdex, Eylea | Uptown Eye Specialists | Diabetic Macular Edema | 08/21 | 12/21 | | |
AURIGA, NCT03161912: A Study to Evaluate the Effectiveness of Intravitreal Aflibercept in Patients With Diabetic Macular Edema and/or Macular Edema Secondary to Retinal Vein Occlusion, Which Either Have or Have Not Been Pretreated for Their Disease |
|
|
| Completed | N/A | 2481 | Europe, RoW | Aflibercept (Eylea, BAY86-5321) | Bayer, Regeneron Pharmaceuticals | Macular Edema | 09/21 | 12/21 | | |
NCT04891835: Analysis of naïve Patients With Age-related Macular Degeneration of the Neovascular Type and Treated With Aflibercept (Eylea®) in "Treat-and-extend" at CHU Brugmann |
|
|
| Completed | N/A | 36 | Europe | Data extraction from medical files | Laurence Postelmans | Age-related Macular Degeneration | 09/21 | 09/21 | | |
| Completed | N/A | 47 | Europe | Aflibercept Injection [Eylea], Navigated laser photocoagulation, Navilas | Odense University Hospital, Danske Regioner, Synoptik-Fonden, Toyota-Fonden, AP Moeller Foundation, Yamagata University, Queen's University, Belfast, Zealand University Hospital, Region Sjællands og Region Syddanmarks forskningspulje | Branch Retinal Vein Occlusion, Macular Edema | 10/21 | 10/21 | | |
ChiCTR2100049055: A multicenter, randomized controlled trial of advanced age-related macular degeneration |
|
|
| Not yet recruiting | N/A | 40 | | IBI302 treatment ;Treatment of EYLEA | Shanghai General Hospital; Shanghai General Hospital, project funding | age-related macular degeneration | | | | |
NCT04882956: BEOVU Versus Eylea in the Treatment of Age-related Macular Neovascular Degeneration |
|
|
| Recruiting | N/A | 40 | RoW | intravitreal injection, BEOVU, Eylea | Benha University | Macula Lutea Degeneration | 12/21 | 03/22 | | |
NCT05080803: Diabetic Macular Edema: Relevance of Staging Progression on Therapeutic Outcome |
|
|
| Completed | N/A | 608 | Europe | intravitreal administration of bevacizumab/ranibizumab/aflibercept/desamethazone | European School of Advanced Studies in Ophthalmology | Diabetic Macular Edema | 12/21 | 07/22 | | |
NCT02081339: Cohort Study of the Clinical Course of Macular Diseases in Japanese |
|
|
| Recruiting | N/A | 1000 | Japan | ranibizumab, aflibercept, pegaptanib, verteporphin | Kyoto University, Graduate School of Medicine | Macular Disease | 03/22 | 03/24 | | |
NCT02550002: Comparison of Treatment rOutine Using afLibERcept: Strict vs relAxed retreatmeNT Regimen |
|
|
| Completed | N/A | 150 | Europe | Aflibercept, Eylea | University Hospital Inselspital, Berne | Age Related Macular Degeneration | 03/22 | 08/22 | | |
| Completed | N/A | 40 | RoW | Phacoemulsification with IVI of aflibercept | Al Hadi Hospital | Diabetic Macular Edema | 08/22 | 12/22 | | |
NAAVA, NCT04137120: Study to Gather Information on the Safety and Use of Aflibercept Injections Into the Eye for the Treatment of Eye Disorders in Mexican Routine Clinical Practice |
|
|
| Completed | N/A | 73 | RoW | Aflibercept (BAY86-5321, Eylea), Eylea®; Eylia®; Wetlia®; VEGF Trap-Eye | Bayer | Retinal Disease | 08/22 | 02/23 | | |
REALM, NCT04524910: A Study to Learn More About How Drug Aflibercept Works in Canadian Patients With Reduced Vision Caused by New Blood Vessels Growing in the Eye (Myopic Choroidal Neovascularization or mCNV) |
|
|
| Completed | N/A | 28 | Canada | Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321) | Bayer | Myopic Choroidal Neovascularization | 10/22 | 11/22 | | |
NCT04707027: Interval of Disease Inactivity After Complete Polypoidal Regression in PCV Receiving Aflibercept |
|
|
| Recruiting | N/A | 80 | RoW | Aflibercept Injection (2 mg/0.05 ml), Eylea, Defer treatment | Chiang Mai University | Polypoidal Choroidal Vasculopathy | 11/22 | 11/23 | | |
NCT03290794: Structured Post-marketing Surveillance to Collect the Safety Data of Intravitreal Aflibercept Injection (IVT-AFL) in Patients of Wet Age-related Macular Degeneration During Real World Clinical Practice |
|
|
| Completed | N/A | 100 | RoW | Aflibercept (Eylea, BAY86-5321) | Bayer | Wet Age-related Macular Degeneration | 11/22 | 05/23 | | |
HERMES Study, NCT02880644: Ultra-wide Fluorescein Angiography in Patients With Central Retinal Vein Occlusion Treated by Afilbercept |
|
|
| Completed | N/A | 65 | Europe | | Centre Hospitalier Intercommunal Creteil, Bayer, Association Clinique Thérapeutique Infantile du val de Marne | Retinal Vein Occlusion | 11/22 | 11/22 | | |
NCT05791695: A Study of the Incidence of Intraocular Inflammation and Suspected Endophthalmitis Among Patients Treated With Aflibercept, Vial and Pre-filled Syringe, 2014-2022 |
|
|
| Completed | N/A | 155413 | US | Non Applicable | Regeneron Pharmaceuticals, Bayer | Intraocular Inflammation, Suspected Endophthalmitis | 12/22 | 09/23 | | |
NCT03297684: Assessment of Biomarker Profile in Diabetic Macular Edema With Intravitreal Aflibercept Injection |
|
|
| Active, not recruiting | N/A | 40 | US | Aflibercept Injection [Eylea] | Advanced Eye Research Associates | Diabetic Macular Edema | 12/22 | 12/22 | | |
| Active, not recruiting | N/A | 49 | Europe | | Centre Hospitalier Intercommunal Creteil, Bayer | AMD, Exudative Macular Degeneration | 01/23 | 07/23 | | |
| Active, not recruiting | N/A | 24 | Europe | AFLIBERCEPT | Poitiers University Hospital | Myopic Choroidal Neovascularisation | 01/23 | 01/23 | | |
ANDROMEDA, NCT03714308: Aflibercept Injection Into the Vitreous Body of the Eye: Study to Learn More About Patient Relevant Outcomes, Real World Treatment Patterns and How Well the Treatment Works for Patients Suffering From Abnormal Growth of New Blood Vessels Under the Retina. |
|
|
| Completed | N/A | 554 | Europe | Ivt. Aflibercept (Eylea, BAY86-5321) | Bayer | Macular Degeneration | 03/23 | 05/23 | | |
CSCR, NCT05847049: Eplerenone, Aflibercept and Topical Nepafenac Serous Foveal Deta Chment in Central Serous Chorioretinopathy |
|
|
| Completed | N/A | 16 | RoW | Eplerenone , Intravitreal Aflibercept and Topical nepafenac therapy | Dar El Oyoun Hospital | Central Serous Chorioretinopathy | 03/23 | 04/23 | | |
RAZORBILL, NCT04662944: A Non-interventional Study to Assess the Influence of Automated Optical Coherence Tomography Image Enrichment With Segmentation Information on Disease Activity Assessment in Patients Treated With Licensed Anti- VEGF Injections |
|
|
| Completed | N/A | 494 | Europe, Canada | brolucizumab, ranibizumab, aflibercept | Novartis Pharmaceuticals | Neovascular Age-Related Macular Degeneration | 06/23 | 06/23 | | |
XTEND, NCT03939767: Assessment of Proactive Treatments in Patients With Wet Age-related Macular Degeneration (wAMD) Which Have Never Undergone Treatment of This Particular Disease |
|
|
| Completed | N/A | 1563 | Europe, Canada, RoW | Aflibercept (Eylea, BAY86-5321) | Bayer | Wet Age-related Macular Degeneration | 07/23 | 10/23 | | |
| Recruiting | N/A | 80 | Europe | Aflibercept | Medical University of Vienna | Age Related Macular Degeneration, Intravitreal Injections, Diabetic Macular Edema | 09/23 | 12/23 | | |
NCT06124677: Single Injection of Faricimab for nAMD With Persisting Fluid Despite Frequent Aflibercept Treatments |
|
|
| Completed | N/A | 46 | Europe | Faricimab, Vabysmo (6 mg, 0.05 ml) | Rigshospitalet, Denmark | Neovascular Age-related Macular Degeneration | 11/23 | 12/23 | | |
NCT02645266: Mean Visual Acuity Changes Following Five Injections of Aflibercept |
|
|
| Active, not recruiting | N/A | 48 | Canada | Aflibercept Injection [Eylea], Eylea treatment | McMaster University | Diabetic Macular Edema | 09/24 | 12/24 | | |
NCT06231121: Switching to Faricimab in Neovascular Age-related Macular Degeneration Resistant to Both Aflibercept and Ranibizumab |
|
|
| Completed | N/A | 13 | Europe | Faricimab, Vabysmo (6 mg, 0.05 ml) | Rigshospitalet, Denmark | Neovascular Age-related Macular Degeneration | 01/24 | 01/24 | | |
ChiCTR2100049698: The association of single nucleotide polymorphism with response to anti-vascular endothelial growth factor treatment in Chinese polypoidal choroidal vasculopathy patients |
|
|
| Not yet recruiting | N/A | 90 | | Intravenous injection of aflibercept | Chinese Academy of Medical Sciences Peking Union Medical College Hospital; Chinese Academy of Medical Sciences Peking Union Medical College Hospital, Special Fundation for Basic Research of Beijing, Tianjin, Hebei Cooperation | polypoidal choroidal vasculopathy | | | | |
NCT06315556: An Observational Study to Collect Data on How Aflibercept (Eylea) Given Using a Paediatric Dosing Device is Used in Preterm Babies With Retinopathy of Prematurity in the United Kingdom (UK) |
|
|
| Recruiting | N/A | 200 | Europe | Aflibercept (Eylea) | Bayer | Retinopathy of Prematurity, Preterm Infants | 03/27 | 04/27 | | |
NCT05211804: Mechanisms of Retinal Revascularization and Clinical Indicators of Neovascular AMD Relapse |
|
|
| Completed | N/A | 31 | Europe | Ophthalmic Drugs, Aflibercept, Bevacizumab, Ranibizumab | Sorlandet Hospital HF | Wet Macular Degeneration | 05/24 | 05/24 | | |
FAR-WEST, NCT06271330: Multicenter Real-life Observational Study Switched Aflibercept or Ranibizumab to Faricimab in Patients With AMD. |
|
|
| Not yet recruiting | N/A | 100 | Europe | Faricimab | Nantes University Hospital, Rennes University Hospital | AMD | 04/25 | 09/26 | | |
